Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.7%.
Currently, Endo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo surpassed first-quarter 2017 earnings. The company reported EPS of $1.23 while our consensus called for EPS of $1.12.
Revenues: Revenues were in line with expectations. Endo posted revenues of $1.03 billion in line with the consensus estimate.
Key Stats: Revenues were up on a year over year basis due to the launch of key first-to-file generic products for Seroquel and Zetia.
2017 Guidance: Endo expects revenues in the range of $3.45 billion to $3.60 billion. The company expects earnings from continuing operations in the range of $3.45 to $3.75 per share. The Zacks Consensus Estimate for earnings is $3.63 per share on revenues of $3.55 billion.
Pre-Market Trading: Shares did not show any movement in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Image: Bigstock
Endo (ENDP) Q1 Earnings Beat Estimates, Revenues in Line
Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.7%.
Currently, Endo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo surpassed first-quarter 2017 earnings. The company reported EPS of $1.23 while our consensus called for EPS of $1.12.
Revenues: Revenues were in line with expectations. Endo posted revenues of $1.03 billion in line with the consensus estimate.
Key Stats: Revenues were up on a year over year basis due to the launch of key first-to-file generic products for Seroquel and Zetia.
2017 Guidance: Endo expects revenues in the range of $3.45 billion to $3.60 billion. The company expects earnings from continuing operations in the range of $3.45 to $3.75 per share. The Zacks Consensus Estimate for earnings is $3.63 per share on revenues of $3.55 billion.
Pre-Market Trading: Shares did not show any movement in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Endo International PLC Price and EPS Surprise
Endo International PLC Price and EPS Surprise | Endo International PLC Quote
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>